Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to -$162.8 million.

  • Keros Therapeutics' Free Cash Flow rose 110.09% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.1 million, marking a year-over-year increase of 161.11%. This contributed to the annual value of -$162.8 million for FY2024, which is 28.22% down from last year.
  • Latest data reveals that Keros Therapeutics reported Free Cash Flow of -$162.8 million as of FY2024, which was down 28.22% from -$127.0 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Free Cash Flow registered a high of -$37.2 million during FY2020, and its lowest value of -$162.8 million during FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$127.0 million (2023), whereas its average is -$120.4 million.
  • Data for Keros Therapeutics' Free Cash Flow shows a maximum YoY tumbled of 128.58% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Keros Therapeutics' Free Cash Flow stood at -$37.2 million in 2020, then slumped by 69.87% to -$63.2 million in 2021, then decreased by 12.87% to -$71.3 million in 2022, then plummeted by 78.07% to -$127.0 million in 2023, then decreased by 28.22% to -$162.8 million in 2024.